Childhood Hodgkin Lymphoma Treatment–Health Professional Version (PDQ®)

SECTIONS

Changes to This Summary (03/31/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Hodgkin Lymphoma

Added Linabery et al. as reference 12.

Diagnosis and Staging Information for Childhood Hodgkin Lymphoma

Added text to state that the Euronet Hodgkin lymphoma trials use a similar early response assessment definition of positron emission tomography (PET) positivity, which is a Deauville score of greater than 3 after two cycles of OEPA (vincristine [Oncovin], etoposide, prednisone, doxorubicin [Adriamycin]). However, the definition for late response assessment after all chemotherapy is a Deauville score of greater than 1 (cited Hasenclever et al. as reference 28).

Treatment for Newly Diagnosed Children and Adolescents with Hodgkin Lymphoma

Revised text to state that omission of radiation for patients completely responding (defined as complete resolution or only minor residuals in all previously involved regions using clinical examination and anatomic imaging) to risk- and gender-based OEPA or OPPA/COPP chemotherapy results in a significantly lower event-free survival in intermediate- and high-risk patients compared with irradiated patients, but no difference among nonirradiated and irradiated patients assigned to the favorable-risk group.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Late Effects from Childhood/Adolescent Hodgkin Lymphoma Therapy

Next section >
About This PDQ Summary